Search results
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 2 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
2 High-Yield Dividend Stocks to Buy Right Now | The Motley Fool
The Motley Fool· 4 days agoDividend stocks are sensitive to interest rates. When rates fall, studies show that money managers...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 1 day agoThe biotech group ranks No. 40 out of 197 industry groups that IBD tracks. Meanwhile, the pharma...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoSo, MRNA stock ranks narrowly inside the top half of all stocks, regardless the industry group, on...
Paxlovid Fails to Quell Long Covid Symptoms in Stanford Study
Bloomberg· 1 day agoA 15-day course of Pfizer Inc.’s antiviral Paxlovid didn’t provide significant relief for long Covid...
Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU
Zacks via Yahoo Finance· 3 days agoHalozyme (HALO) is set to benefit from the new patent grant in the EU, ensuring the protection of...
AbbVie's tight grip on Humira market raises concerns about biosimilars
Colorado Springs Gazette· 2 days agoHumira, which lists for almost $7,000 a month, is the first top-selling drug to compete with a slew of biosimilars, which are close but not exact copies of branded biologic ...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 1 day agoShares continued to climb, hitting a recent intraday high at 23.86 on June 6. Shares now have a top...
Germany’s Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions – Interview
The Wall Street Journal· 2 days agoMerck—known as EMD Group in the U.S.— is betting on artificial-intelligence partnerships to develop...
NJ health care, pharmaceutical companies cutting jobs as tech disrupts industry
The Bergen Record via Yahoo News· 2 days ago“This shift is also due to changes in research and development, drug failures, the end of...